Vertex’s Bet on T1D, AZ’s Win in T2D CV Outcomes, & FDA Commish Speculation

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

A Glimmer of Hope, and a Premature Celebration
Meet My Friend Who Supported Trump in 2016
Keeping the Faith and Bracing for the Long Slog
A Time for Empathy